Publications by authors named "S Kopetz"
Purpose: Appendiceal adenocarcinoma (AA) is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of AA relative to common tumors.
Experimental Design: We analyzed molecular data for patients within the Guardant Health database with appendix cancer (n = 718).
Article Synopsis
- Bulk deconvolution using single-cell RNA-seq is important for analyzing complex biological samples, but differences in sequencing technology can lead to inaccuracies.
- The researchers created a new framework called DeMixSC that improves deconvolution by utilizing well-matched benchmark datasets to account for these technological discrepancies.
- DeMixSC was tested on datasets from healthy retinas and ovarian cancer tissues, showing improved accuracy and the ability to reveal significant biological differences in patient groups, highlighting its usefulness in clinical applications.
Background: As liver metastasis is the most common cause of mortality in patients with colorectal cancer, studying colorectal cancer liver metastasis (CLM) microenvironment is essential for improved understanding of tumor biology and to identify novel therapeutic targets.
Methods: We used a multiplex immunofluorescence platform to study tumor associated macrophage (TAM) polarization and adaptive T cell subtypes in tumor samples from 105 CLM patients (49 without and 56 with preoperative chemotherapy).
Results: CLM exhibited M2 macrophage polarization, and helper T cells were the prevalent adaptive T cell subtype.
Background: Immune checkpoint blockade (ICB) has revolutionized treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). However, there is no evidence on the optimal treatment duration. We aimed to compare outcomes of different immunotherapy durations.
View Article and Find Full Text PDFThe BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the United States and the European Union. A greater understanding of biomarkers predictive of response to Enco+Cetux±Bini treatment is of clinical relevance. In this prespecified, exploratory biomarker analysis of the BEACON CRC study, we characterize genomic and transcriptomic correlates of clinical outcomes and acquired resistance mechanisms through integrated clinical and molecular analysis, including whole-exome and -transcriptome tissue sequencing and circulating tumor DNA genomic profiling.
View Article and Find Full Text PDF